Comparative Pharmacology
Head-to-head clinical analysis: ANTARA MICRONIZED versus FENOFIBRATE MICRONIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTARA MICRONIZED versus FENOFIBRATE MICRONIZED.
ANTARA (MICRONIZED) vs FENOFIBRATE (MICRONIZED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor alpha (PPARα). This leads to increased lipolysis and elimination of triglyceride-rich particles from plasma by inducing lipoprotein lipase activity and reducing production of apolipoprotein C-III.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. It also increases apoproteins A-I and A-II, leading to increased HDL cholesterol.
Oral: 130 mg once daily with or without food. Capsules should be swallowed whole; do not crush or chew.
Fenofibrate (micronized) 145 mg orally once daily; alternatively 48 mg orally once daily to 145 mg orally once daily as tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 15–17 hours (range 13–22 hours) in normolipidemic subjects; in hypertriglyceridemic patients, half-life may be prolonged up to 24–33 hours due to increased volume of distribution. Repeated dosing leads to steady state by about 4–5 days.
Terminal half-life of fenofibric acid is approximately 20 hours (range 19–27 hours) in adults, allowing once-daily dosing.
Renal (approximately 70% of a dose is excreted in the urine, primarily as the glucuronide conjugate; less than 10% is excreted as unchanged drug in urine); fecal/biliary elimination accounts for about 20% (mainly as unchanged drug and metabolites via bile).
Renal: 60% (as fenofibric acid and glucuronide conjugates); Fecal: 25%; Biliary: minor.
Category C
Category A/B
Fibrate
Fibrate